IVI to Present at ISPOR 2024 Annual Conference

Alexandria, VA – May 1, 2024 – The Innovation and Value Initiative (IVI), a non-profit research organization committed to advancing the science, practice, and use of health technology assessment (HTA) in healthcare, today announced its participation at ISPOR 2024, May 5-8, 2024, at the Georgia World Congress Center in Atlanta. IVI will present six posters throughout […]

IVI Releases IRA Symposium Proceedings Report

On December 5, 2023, the Innovation and Value Initiative (IVI), the Alliance for Aging Research, National Pharmaceutical Council, and Leavitt Partners, LLC, hosted a half-day symposium to examine issues related to equity and patient engagement in implementation of the Inflation Reduction Act of 2022 (IRA) by the Centers for Medicare & Medicaid Services (CMS). This […]

VIDEO: Bridging the Gap, Empowering Patients: A Collaborative Approach to Rare Disease Research

In celebration or Rare Disease Awareness Month, the video “Bridging the Gap, Empowering Patients: A Collaborative Approach to Rare Disease Research” highlights the significance of adopting a collaborative, patient-centered approach in rare disease research. Led by the Innovation and Value Initiative and Alexion, AstraZeneca Rare Disease, the conversation underscores the importance of transforming the future […]

IVI Hosts its 4th Annual Meeting

The Innovation and Value Initiative (IVI) is pleased to announce the completion of its 4th Annual Meeting, our second in-person meeting since the pandemic. We were thrilled to see our esteemed members, partners, and colleagues participate in many important discussions. This year, we featured multiple IVI research initiatives, including the IVI Major Depressive Disorder (IVI-MDD) […]

IVI Responds to CMS’ Announcement of Prescription Drugs under the Inflation Reduction Act

Alexandria, VA – August 29, 2023 – The Innovation and Value Initiative (IVI), a non-profit research organization committed to advancing the science, practice, and use of health technology assessment in health care, today issued a statement in response to the Centers for Medicare and Medicaid Services’ (CMS) announcement of the first prescription drugs selected for price negotiations under the Inflation […]

Maximizing Value and Equity: CMS Must Prioritize Value, Equity, and Patient Engagement in Drug Price Negotiation Program Implementation

By Jason Spangler, MD, MPH, FACPM (CEO, Innovation and Value Initiative) In March, the Centers for Medicare and Medicaid Services (CMS) released draft guidance for its implementation of the Drug Price Negotiation Program (DPNP), a key component of the Inflation Reduction Act (IRA). This release and its associated comment period sparked far-ranging debate and a […]

IVI Responds to the ICER 2023 Value Assessment Framework

IVI submitted comments on the ICER 2023 Value Assessment Framework. We appreciate the opportunity to provide comments on this important issue. In revising its value assessment framework, IVI recommends that ICER make modifications related to proposed methodological changes, patient engagement strategies, and methods for handling data gaps to increase equity within health technology assessment. Read […]

IVI Announces Leadership Update

It is with mixed emotions we announce that Jennifer Bright, MPA, will be stepping down from her position as Chief Strategy and Engagement Officer effective June 30th. Ms. Bright joined IVI in 2017 and served as the organization’s first Executive Director and then Chief Executive Officer until July 2022, when she transitioned into her current […]

IVI Partners with AcademyHealth to Address Economic Impacts on Patients and Caregivers

IVI, in partnership with AcademyHealth, released a joint report, “A Research Framework to Understand the Full Range of Economic Impacts on Patients and Caregivers,” for researchers, value assessors, and other decision-makers to address the full range of economic impacts on patients. This report was made possible through funding support from the Eugene Washington PCORI Engagement […]

IVI Comments on CMS’ Medicare Drug Price Negotiation Program

IVI submitted comments on the Centers for Medicare and Medicaid Services’ (CMS) initial guidance for the implementation of the Medicare Drug Price Negotiation Program (Medicare DPNP). We appreciate the opportunity to provide comment on this important issue. Read our full comments here. ### About IVI The Innovation and Value Initiative (IVI) is a 501(c)(3) tax-exempt, […]